An article from
Dive Brief
Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
Published July 6, 2026
Getty Images
Cancer, immune drugmakers dominate VC funding so far in 2026
Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
489 words~2 min read
